<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Br. J. Cancer</journal-id><journal-title-group><journal-title>British Journal of Cancer</journal-title></journal-title-group><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10390007</article-id><article-id pub-id-type="pmc">2363002</article-id><article-id pub-id-type="pii">6690350</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6690350</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Waters</surname><given-names>J S</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Norman</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Cunningham</surname><given-names>D</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Scarffe</surname><given-names>J H</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Webb</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Harper</surname><given-names>P</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Joffe</surname><given-names>J K</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Mackean</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Mansi</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Leahy</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hill</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Oates</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Rao</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Nicolson</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hickish</surname><given-names>T</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><aff id="aff1">Cancer Research Campaign (CRC) Section of Medicine and Gastrointestinal Unit, Royal Marsden Hospital and Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, UK</aff><aff id="aff2">CRC Department of Medical Oncology, Christie Hospital, Wilmslow Road, Manchester M20 4BX, UK</aff><aff id="aff3">Department of Medical Oncology, Guys Hospital, St Thomas Street, London SE1 9RT, UK</aff><aff id="aff4">Imperial Cancer Research Fund Cancer Medicine Research Unit, St James University Hospital, Beckett Street, Leeds LS9 7TF, UK</aff><aff id="aff5">CRC Department of Medical Oncology, University of Glasgow, Alexander Stone Building, Garscube Estate, Switchback Road, Bearsden Glasgow G61 1BD, UK</aff><aff id="aff6">Department of Medical Oncology, St Georges Hospital, Blackshaw Road, London SW17 0QT, UK</aff></contrib-group><pub-date pub-type="ppub"><month>4</month><year>1999</year></pub-date><volume>80</volume><issue>1-2</issue><fpage>269</fpage><lpage>272</lpage><history><date date-type="received"><day>27</day><month>08</month><year>1998</year></date><date date-type="rev-recd"><day>04</day><month>11</month><year>1998</year></date><date date-type="accepted"><day>06</day><month>11</month><year>1998</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 1999 Cancer Research Campaign</copyright-statement><copyright-year>1999</copyright-year><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>We report the final results of a prospectively randomized study that compared the combination of epirubicin, cisplatin and protracted venous infusion fluorouracil (5-FU) (ECF regimen) with the standard combination of 5-FU, doxorubicin and methotrexate (FAMTX) in previously untreated patients with advanced oesophagogastric cancer. Between 1992 and 1995, 274 patients with adenocarcinoma or undifferentiated carcinoma were randomized from eight oncology centres in the UK and analysed for response and survival. The overall response rate was 46&#x00025; (95&#x00025; confidence interval (CI), 37&#x02013;55&#x00025;) with ECF, and 21&#x00025; (95&#x00025; CI, 13&#x02013;28&#x00025;) with FAMTX (<italic>P</italic> = 0.00003). The median survival was 8.7 months with ECF and 6.1 months with FAMTX (<italic>P</italic> = 0.0005). The 2-year survival rates were 14&#x00025; (95&#x00025; CI, 8&#x02013;20&#x00025;) for the ECF arm, and 5&#x00025; (95&#x00025; CI, 2&#x02013;10&#x00025;) for the FAMTX arm (<italic>P</italic> = 0.03). Histologically complete surgical resection following chemotherapy was achieved in ten patients in the ECF arm (three pathological complete responses to chemotherapy) and three patients in the FAMTX arm (no pathological complete responses). The ECF regimen resulted in a response and survival advantage compared with FAMTX chemotherapy. The probability of long-term survival following surgical resection of residual disease is increased by this treatment. The high response rates seen with ECF support its use in the neoadjuvant setting. &#x000a9; 1999 Cancer Research Campaign</p></abstract><kwd-group><kwd>cancer</kwd><kwd>chemotherapy</kwd><kwd>ECF</kwd><kwd>FAMTX</kwd><kwd>gastric</kwd><kwd>oesophagogastric</kwd></kwd-group></article-meta></front></article>
